Linked Life Data

17591804

Source:http://linkedlifedata.com/resource/pubmed/id/17591804

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:dateCreated
2007-6-26
pubmed:abstractText
Gastric cancer is still a major health problem and a leading cause of cancer mortality despite a worldwide decline in incidence. Surgery is the primary curative treatment of locoregional gastric cancer. In Western countries, however, at the time of resection, most patients are expected to have regional lymph node involvement with poor prognostic implications. To improve these results, different trials have been carried out in the adjuvant or neo-adjuvant setting. Many phase III trials of adjuvant therapy have been conducted; however, postoperative treatment modalities have not proven to be superior to postsurgical observation alone. Therefore, at present the routine use of adjuvant therapy should be regarded as an investigational approach. Improved clinical trial designs with standardized surgical techniques and the incorporation of newer active drugs are needed. On the contrary, neo-adjuvant chemotherapy has shown promising results as suggested by the final results of UK Medical Research Council Adjuvant Gastric Infusional Chemotherapy trial.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jun
pubmed:issn
0923-7534
pubmed:author
pubmed:issnType
Print
pubmed:volume
18 Suppl 6
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
vi120-3
pubmed:dateRevised
2007-11-15
pubmed:meshHeading
pubmed:year
2007
pubmed:articleTitle
Neo-adjuvant and adjuvant chemotherapy of gastric cancer.
pubmed:affiliation
Division of Medical Oncology, Surgical Oncology, F. Magrassi & A. Lanzara, Department of Clinical and Experimental Medicine, Second University of Naples School of Medicine, Naples, Italy. fernandodevita@yahoo.it
pubmed:publicationType
Journal Article, Review